Navigation Links
Some Oral Contraceptives May Reduce Pregnancy Chances in In Vitro Fertilization (IVF), According to New Research by CHR
Date:5/6/2013

New York, NY (PRWEB) May 06, 2013

Some oral contraceptives with stronger androgenic characteristics may reduce pregnancy chances with IVF, reports a new study conducted by the Center for Human Reproduction (CHR), a research-driven fertility center in New York City.

The study, just published in Reproductive Biology and Endocrinology(1), investigated 43 young oocyte (egg) donors, some of whom were taking various forms of oral contraceptives. According to the study, donors who took contraceptives with stronger androgenic characteristics before their treatment cycles had significantly lower number of eggs retrieved after ovarian stimulation. Donors who took androgenic contraceptives developed 11 eggs on average, while those with no contraceptives had 16, and those using anti-androgenic contraceptives had 19.

Because oral contraceptives suppress secretion of gonadotropins from the pituitary, hormonal contraceptive use may lead to suppression of ovarian function, interrupting the normal development of eggs in the ovaries. Lower egg yields after ovarian stimulation is also likely to result in lower IVF pregnancy rates.

“Many fertility centers routinely use oral contraceptives in preparatory stages of IVF cycles,” says David H. Barad, MD, MS, Director of Clinical ART and Senior Scientist at CHR, who is the lead author of the study. “Our results show that this routine use of oral contraceptives before IVF may have a negative impact on oocyte numbers, and may require rethinking on the part of treating physicians.

In the study, some hormonal contraceptives’ negative effects on oocyte yields were apparent even in young oocyte donors with normal ovarian reserve. “These negative effects on IVF outcomes may be even greater in women with diminished ovarian reserve,” cautions Dr. Barad, “who already produce only a small number of eggs under the best of circumstances.”

The study is the first to report on the potentially negative effects of at least some hormonal contraceptives on IVF outcomes. Larger studies are needed to determine whether use of some forms of oral contraceptives should be avoided in the context of fertility treatments.

(1)Barad DH, Kim A, Kubba H, Weghofer A and Gleicher N. Does hormonal contraception prior to in vitro fertilization (IVF) negatively affect oocyte yields? – A pilot study. Reprod Biol Endocrinol 2013;11:28.

About Center for Human Reproduction
The Center for Human Reproduction (https://www.centerforhumanreprod.com/), located in New York City, is one of the world’s leading fertility centers. As "fertility center of last resort,” CHR has treated countless women with diminished ovarian reserve (DOR), whether due to advanced age or premature ovarian aging (POA). To serve its patient population, Dr. Barad is available for further comments.

Read the full story at http://www.prweb.com/releases/pregnancychanceswithivf/birthcontrol/prweb10701484.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. More Teen Girls Using Contraceptives: CDC
2. Blood Clot Risk Linked to Some Non-Pill Contraceptives
3. 70 percent of women use contraceptives during their first sexual encounter
4. IUDs Safe Contraceptives for Teens, Study Finds
5. Huntingtons Disease Linked to Reduced Cancer Risk in Study
6. BMC study shows diverting passengers to elevators could help reduce falls at Logan Airport
7. Decision guide reduced uncertainty over breast cancer prevention, study finds
8. Scoliosis Treatment Might Reduce Need for Surgeries
9. Exercise helps smokers to quit smoking, to remain smoke-free and to reduce the risk of death
10. Additional blood pressure screening may reduce incidence of CVD events and death by up to 3 percent
11. Groundbreaking Nigeria summit results in major commitment to reduce child deaths
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... ... February 24, 2017 , ... Rosica ... in thought leadership , media relations, social media, content marketing and SEO, ... be powered through Act-On, an intuitive marketing automation platform. , Rosica will now ...
(Date:2/23/2017)... ... 23, 2017 , ... On February 22, 2017 the U.S. ... to withdraw previous guidance issued by the Obama Administration requiring schools to treat ... 2016 by the Obama Administration came in response to a growing number of ...
(Date:2/23/2017)... , ... February 23, 2017 , ... The American Cleft ... ACPA’s 74th Annual Meeting. KLS is a longtime supporter of the event. , ... exhibitor and Platinum Sponsor," said Dr. Bob Havlik, 2017 ACPA President. "KLS Martin has ...
(Date:2/23/2017)... ... February 23, 2017 , ... EBSCO Information Services ... Institute for Health and Care Excellence (NICE) framework. The agreement allows purchasers ... (NHS) to search, order and purchase medical and healthcare-related content through GOBI ...
(Date:2/23/2017)... ... , ... ERT, a global data and technology company that ... leading clinical development service provider, has selected ERT’s Trial Oversight suite as its ... to an array of circumstances including the use of multiple data capture modalities ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... DUBLIN , Feb 24, 2017 Research ... Drugs Price Analysis and Strategies - 2016" report to their ... The ... provides drug pricing data and benchmarks in the global Urinary Incontinence ... What are the key drugs marketed for Urinary Incontinence ...
(Date:2/23/2017)... -- Cogentix Medical, Inc. (NASDAQ: CGNT), a medical device company ... the urology market, will release financial results for the ... before the market open on Thursday, March 9, 2017. ... call and webcast to discuss its financial results the ... a.m. Eastern Time (10:00 a.m. Central Time). Darin ...
(Date:2/23/2017)... 23, 2017 Research and Markets has announced ... Strategies - 2016" report to their offering. ... The latest research Oesophageal Cancer ... and benchmarks in the global Oesophageal Cancer market. The ... are the key drugs marketed for Oesophageal Cancer and their clinical ...
Breaking Medicine Technology: